Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib With or Without Whole Brain Radiotherapy in EGFR-Mutant NSCLC With Brain Metastases
NCT02338011Phase 3Unknown
- Sponsor
- Shanghai Chest Hospital
- Start
- Nov 2014
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gefitinib in non-small cell lung cancer (NSCLC) and brain metastases (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoint: Time to progression. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on NCT02338011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02338011.